What is Co-Diagnostics Inc's earnings per share (EPS)?

Co-Diagnostics Inc (CODX) reported diluted earnings per share of -$35.25 for fiscal year 2025. This represents a 5.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Co-Diagnostics Inc Financials

CODX

FY2025 annual

Revenue $622K -84.1% YoY

Net Income -$47.0M -23.7% YoY

EPS (Diluted) -$35.25 +5.3% YoY

Free Cash Flow -$29.8M +0.2% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Co-Diagnostics Inc (CODX) reported $622K in revenue for fiscal year 2025, down 84.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CODX FY2025 2026-08-13

With revenue down to $622K, Co-Diagnostics now operates more like a cash-funded development program than a self-sustaining commercial business.

Operating cash outflow of $29.1M was far larger than year-end cash of $11.9M. Cash persisted only because $26.3M came from investing inflows and $11.8M from financing, showing the company is being funded by balance-sheet actions and outside capital rather than customers.

The cost base is now unmistakably development-led: R&D was $19.1M against revenue of just $622K. SG&A fell to $9.1M, which suggests overhead has been cut, but the loss is now driven mainly by fixed operating spend rather than by the economics of each sale.

The balance sheet remains lightly levered—liabilities were only $4.1M against equity of $20.6M—so the immediate issue is runway, not debt service. The deeper change is shrinkage: assets fell from $160.0M at the earlier high point to $24.7M, showing repeated losses have been absorbed mainly by the company's own resources rather than by borrowing.

Financial Health Signals

Financial health score not available

Co-Diagnostics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-9.61

Co-Diagnostics Inc scores -9.61, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.6M) relative to total liabilities ($4.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Co-Diagnostics Inc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Co-Diagnostics Inc reported a net loss of $47.0M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$622K

YoY-84.1%

5Y CAGR-61.6%

Co-Diagnostics Inc generated $622K in revenue in fiscal year 2025. This represents a decrease of 84.1% from the prior year.

EBITDA

-$49.1M

YoY-26.8%

Co-Diagnostics Inc's EBITDA was -$49.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.8% from the prior year.

Net Income

-$47.0M

YoY-23.7%

Co-Diagnostics Inc reported -$47.0M in net income in fiscal year 2025. This represents a decrease of 23.7% from the prior year.

EPS (Diluted)

-$35.25

YoY+5.3%

Co-Diagnostics Inc earned -$35.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$29.8M

YoY+0.2%

Co-Diagnostics Inc recorded an outflow of $29.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 0.2% from the prior year.

Cash & Debt

$11.9M

YoY+304.7%

5Y CAGR-22.7%

Co-Diagnostics Inc held $11.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

YoY+90.1%

Co-Diagnostics Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 90.1% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

64.3%

YoY-10.2pp

5Y CAGR-13.5pp

Co-Diagnostics Inc's gross margin was 64.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.2 percentage points from the prior year.

Return on Equity

-227.8%

YoY-157.3pp

5Y CAGR-291.5pp

Co-Diagnostics Inc's ROE was -227.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 157.3 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$19.1M

YoY-8.8%

5Y CAGR+43.1%

Co-Diagnostics Inc invested $19.1M in research and development in fiscal year 2025. This represents a decrease of 8.8% from the prior year.

Capital Expenditures

$700K

YoY-6.5%

5Y CAGR-2.0%

Co-Diagnostics Inc invested $700K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 6.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CODX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CODX annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	$721K	$622K-84.1%	$3.9M-42.5%	$6.8M-80.1%	$34.2M-65.0%	$97.9M+31.3%	$74.6M+34579.9%	$215K+438.6%	$40K+420.9%	$8K	N/A
Cost of Revenue	$408K	$222K-77.7%	$999K-76.1%	$4.2M-23.6%	$5.5M-52.6%	$11.6M-30.2%	$16.6M+14656.9%	$112K+1097.2%	$9K+3009.6%	$302	N/A
Gross Profit	$314K	$400K-86.3%	$2.9M+11.0%	$2.6M-90.9%	$28.7M-66.7%	$86.3M+48.9%	$58.0M+56424.0%	$103K+236.0%	$31K+314.7%	$7K	N/A
R&D Expenses	$19.7M	$19.1M-8.8%	$21.0M-8.6%	$23.0M+31.7%	$17.4M+16.5%	$15.0M+369.7%	$3.2M+132.3%	$1.4M+0.8%	$1.4M+35.7%	$1.0M+37.1%	$731K
SG&A Expenses	$7.7M	$9.1M-43.9%	$16.2M+13.1%	$14.3M+0.1%	$14.3M+23.5%	$11.6M+39.5%	$8.3M+136.7%	$3.5M-2.1%	$3.6M+15.3%	$3.1M+288.5%	$797K
Operating Income	-$49.0M	-$50.2M-25.2%	-$40.1M+6.1%	-$42.7M-58.3%	-$27.0M-158.6%	$46.1M+10.5%	$41.7M+807.4%	-$5.9M+3.7%	-$6.1M-34.0%	-$4.6M-170.4%	-$1.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$106K+49.9%	$71K-77.1%	$310K+28.9%	$241K
Income Tax	-$1.6M	-$1.6M-2916.9%	$57K+102.1%	-$2.8M+39.7%	-$4.6M-151.3%	$9.0M+9815.6%	$91K	N/A	N/A	N/A	N/A
Net Income	-$47.2M	-$47.0M-23.7%	-$38.0M-7.5%	-$35.3M-148.2%	-$14.2M-138.8%	$36.7M-13.7%	$42.5M+785.6%	-$6.2M+1.2%	-$6.3M+9.9%	-$7.0M-260.8%	-$1.9M
EPS (Diluted)	—	-$35.25+5.3%	-$37.22	-$1.20-166.7%	-$0.45-136.6%	$1.23-19.1%	$1.52	-$0.37	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$166K+13.8%	$146K-44.7%	$264K+81.5%	$145K-10.8%	$163K+224.0%	$50K-66.3%	$149K-76.7%	$641K
Cost of Revenue	$45K-76.6%	$194K+36.1%	$142K+441.7%	$26K-18.1%	$32K+48.7%	$22K-91.5%	$255K-14.2%	$297K
Gross Profit	$121K+352.7%	-$48K-139.3%	$122K+2.0%	$119K-9.0%	$131K+356.0%	$29K+127.1%	-$106K-130.8%	$344K
R&D Expenses	$4.2M-30.0%	$5.9M+16.4%	$5.1M+13.8%	$4.5M-4.4%	$4.7M-3.7%	$4.9M+1.3%	$4.8M-1.5%	$4.9M
SG&A Expenses	$1.5M-40.0%	$2.5M+33.9%	$1.9M+2.9%	$1.8M-30.2%	$2.6M-6.2%	$2.8M-52.3%	$5.8M+35.7%	$4.3M
Operating Income	-$6.2M+32.7%	-$9.2M+65.3%	-$26.5M-278.4%	-$7.0M+13.0%	-$8.1M+5.8%	-$8.6M+28.2%	-$11.9M-16.3%	-$10.2M
Income Tax	$19K+3586.2%	$520+100.1%	-$474K+59.4%	-$1.2M-9563.7%	$12K+2.7%	$12K+246.8%	-$8K-136.8%	$22K
Net Income	-$6.3M+31.2%	-$9.1M+64.6%	-$25.8M-339.1%	-$5.9M+23.8%	-$7.7M-2.6%	-$7.5M+33.9%	-$11.4M-17.5%	-$9.7M
EPS (Diluted)	-$1.46	-$4.06	N/A	-$0.16	-$7.00+0.7%	-$7.05	N/A	-$0.32

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

CODX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CODX annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$24.7M-61.1%	$63.6M-33.3%	$95.3M-22.6%	$123.1M-23.1%	$160.0M+124.6%	$71.2M+3115.7%	$2.2M+42.6%	$1.6M-66.7%	$4.7M+259.8%	$1.3M
Current Assets	$13.7M-57.6%	$32.3M-48.0%	$62.1M-33.0%	$92.7M-19.4%	$115.1M+69.8%	$67.8M+4180.5%	$1.6M+50.6%	$1.1M-76.4%	$4.5M+268.4%	$1.2M
Cash & Equivalents	$11.9M+304.7%	$2.9M-80.3%	$14.9M-35.1%	$23.0M-74.1%	$88.6M+106.2%	$43.0M+4711.9%	$893K-6.0%	$950K-73.1%	$3.5M+253.9%	$999K
Inventory	$992K-7.5%	$1.1M-35.6%	$1.7M-68.7%	$5.3M+165.0%	$2.0M-74.9%	$8.0M+3955.0%	$197K+986.1%	$18K+100.2%	$9K	N/A
Accounts Receivable	$190K+43.6%	$133K-56.4%	$304K-91.2%	$3.5M-83.4%	$20.8M+71.7%	$12.1M+9137.8%	$131K+879.0%	$13K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	$14.7M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.1M-57.5%	$9.7M+4.1%	$9.3M+8.6%	$8.6M-66.5%	$25.6M+462.9%	$4.5M+849.8%	$478K-81.7%	$2.6M+221.8%	$812K-81.1%	$4.3M
Current Liabilities	$3.5M-51.6%	$7.3M+27.3%	$5.7M+48.4%	$3.9M-69.3%	$12.6M+210.1%	$4.1M+1138.4%	$328K-86.1%	$2.4M+274.4%	$628K-83.7%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.9M+587.2%	$278K	N/A
Total Equity	$20.6M-61.7%	$53.9M-37.0%	$85.6M-25.3%	$114.5M-14.8%	$134.5M+101.6%	$66.7M+3739.2%	$1.7M+264.1%	-$1.1M-127.5%	$3.9M+228.6%	-$3.0M
Retained Earnings	-$80.4M-140.1%	-$33.5M-828.1%	$4.6M-88.5%	$39.9M-26.3%	$54.2M+209.3%	$17.5M+170.1%	-$25.0M-33.6%	-$18.7M-50.5%	-$12.4M-127.4%	-$5.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$16.6M-22.8%	$21.5M-13.1%	$24.7M-44.7%	$44.7M-3.7%	$46.5M-15.7%	$55.1M-13.2%	$63.6M-12.2%	$72.4M
Current Assets	$5.2M-46.9%	$9.8M-28.6%	$13.7M-2.6%	$14.1M-8.2%	$15.3M-35.8%	$23.8M-26.2%	$32.3M-19.5%	$40.1M
Cash & Equivalents	$3.6M-55.7%	$8.2M-30.7%	$11.9M+3.9%	$11.4M+3.0%	$11.1M+484.1%	$1.9M-35.2%	$2.9M-72.8%	$10.8M
Inventory	$842K-0.5%	$846K-14.7%	$992K-9.0%	$1.1M+0.5%	$1.1M+0.1%	$1.1M+1.0%	$1.1M-15.3%	$1.3M
Accounts Receivable	$52K-36.8%	$82K-56.7%	$190K+240.5%	$56K-73.5%	$211K+54.7%	$136K+2.9%	$133K-25.6%	$178K
Total Liabilities	$3.9M-28.9%	$5.5M+32.7%	$4.1M-16.3%	$4.9M-7.8%	$5.3M-26.3%	$7.2M-25.4%	$9.7M+12.7%	$8.6M
Current Liabilities	$2.9M-33.2%	$4.3M+21.0%	$3.5M-4.1%	$3.7M-0.5%	$3.7M-31.0%	$5.4M-26.5%	$7.3M+26.2%	$5.8M
Total Equity	$12.7M-20.8%	$16.0M-22.2%	$20.6M-48.2%	$39.8M-2.1%	$40.7M-14.3%	$47.5M-11.9%	$53.9M-15.5%	$63.8M
Retained Earnings	-$95.8M-7.0%	-$89.5M-11.4%	-$80.4M-48.3%	-$54.2M-12.2%	-$48.3M-19.1%	-$40.6M-21.2%	-$33.5M-52.1%	-$22.0M

CODX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CODX annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$27.1M	-$29.1M+0.1%	-$29.2M-32.0%	-$22.1M-436.2%	$6.6M-84.0%	$41.1M+45.9%	$28.2M+609.8%	-$5.5M-35.4%	-$4.1M-27.0%	-$3.2M-144.7%	-$1.3M
Capital Expenditures	$367K	$700K-6.5%	$748K-45.2%	$1.4M-4.4%	$1.4M+113.2%	$669K-13.6%	$774K+583.8%	$113K+174.0%	$41K-68.0%	$129K+956.3%	$12K
Free Cash Flow	-$27.5M	-$29.8M+0.2%	-$29.9M-27.5%	-$23.4M-556.1%	$5.1M-87.3%	$40.4M+47.5%	$27.4M+585.8%	-$5.6M-36.8%	-$4.1M-23.4%	-$3.3M-152.2%	-$1.3M
Investing Cash Flow	$1.5M	$26.3M+53.9%	$17.1M+10.9%	$15.4M+126.5%	-$58.2M-1519.2%	$4.1M+170.4%	-$5.8M-1238.2%	-$435K-14.4%	-$380K-100.9%	-$189K-1446.5%	-$12K
Financing Cash Flow	$18.1M	$11.8M+11266.7%	$104K+107.6%	-$1.4M+90.3%	-$14.0M-3215.9%	$450K-97.7%	$19.7M+234.4%	$5.9M+214.6%	$1.9M-68.4%	$5.9M+159.3%	$2.3M
Share Buybacks	N/A	N/A	N/A	$1.4M-90.4%	$14.2M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$7.2M+8.8%	-$7.8M-26.6%	-$6.2M-5.0%	-$5.9M+28.8%	-$8.3M+5.2%	-$8.7M-6.2%	-$8.2M-13.9%	-$7.2M
Capital Expenditures	$18K-87.1%	$142K+7.6%	$132K+75.7%	$75K-81.3%	$401K+336.3%	$92K+25.9%	$73K-58.2%	$174K
Free Cash Flow	-$7.2M+10.2%	-$8.0M-26.2%	-$6.3M-5.9%	-$6.0M+31.2%	-$8.7M+1.7%	-$8.8M-6.4%	-$8.3M-12.2%	-$7.4M
Investing Cash Flow	-$168K-18.5%	-$142K+56.9%	-$329K-115.1%	$2.2M-87.3%	$17.1M+132.0%	$7.4M+2665.7%	$266K-93.6%	$4.2M
Financing Cash Flow	$2.7M-36.8%	$4.3M-37.8%	$7.0M+71.7%	$4.1M+846.0%	$429K+20.9%	$355K	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

CODX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CODX annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Gross Margin	64.3%-10.2pp	74.5%+35.9pp	38.6%-45.4pp	84.0%-4.2pp	88.2%+10.4pp	77.8%+30.0pp	47.7%-28.8pp	76.5%-19.6pp	96.1%	N/A
Operating Margin	-8058.8%	-1023.8%	-626.9%	-78.8%-125.9pp	47.1%-8.9pp	55.9%	-2741.6%	-15328.6%	-59567.6%	N/A
Net Margin	-7550.3%	-970.6%	-518.7%	-41.6%-79.1pp	37.5%-19.5pp	57.0%	-2882.0%	-15714.3%	-90827.9%	N/A
Return on Equity	-227.8%-157.3pp	-70.5%-29.2pp	-41.3%-28.9pp	-12.4%-39.7pp	27.3%-36.4pp	63.7%+420.3pp	-356.6%	N/A	-180.7%	N/A
Return on Assets	-190.0%-130.2pp	-59.8%-22.7pp	-37.1%-25.5pp	-11.6%-34.5pp	22.9%-36.7pp	59.6%+339.3pp	-279.7%+124.1pp	-403.8%-254.5pp	-149.3%-0.4pp	-148.8%
Current Ratio	3.87-0.5x	4.41-6.4x	10.81-13.1x	23.94+14.8x	9.14-7.6x	16.69+11.9x	4.83+4.4x	0.45-6.6x	7.09+6.8x	0.31
Debt-to-Equity	0.200.0x	0.18+0.1x	0.110.0x	0.07-0.1x	0.19+0.1x	0.07-0.2x	0.28	N/A	0.07	N/A
FCF Margin	-4793.2%	-763.8%	-344.2%	15.0%-26.3pp	41.3%+4.5pp	36.7%	-2622.8%	-10326.4%	-43601.0%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	72.7%+105.5pp	-32.8%-78.8pp	46.1%-35.9pp	81.9%+1.6pp	80.3%+23.2pp	57.1%+127.9pp	-70.8%-124.4pp	53.6%
Operating Margin	-3732.5%	-6309.1%	-10056.7%	-4824.5%	-4946.1%	-17009.7%	-7973.9%	-1596.4%
Net Margin	-3782.4%	-6262.3%	-9794.5%	-4049.3%	-4745.0%	-14983.5%	-7629.1%	-1512.4%
Return on Equity	-49.4%+7.5pp	-57.0%+68.3pp	-125.3%-110.5pp	-14.8%+4.2pp	-19.0%-3.1pp	-15.9%+5.3pp	-21.1%-5.9pp	-15.2%
Return on Assets	-37.9%+4.6pp	-42.5%+62.0pp	-104.5%-91.3pp	-13.2%+3.5pp	-16.6%-3.0pp	-13.7%+4.3pp	-17.9%-4.5pp	-13.4%
Current Ratio	1.81-0.5x	2.28-1.6x	3.87+0.1x	3.81-0.3x	4.12-0.3x	4.430.0x	4.41-2.5x	6.92
Debt-to-Equity	0.310.0x	0.34+0.1x	0.20+0.1x	0.120.0x	0.130.0x	0.150.0x	0.180.0x	0.13
FCF Margin	-4316.7%	-5473.2%	-2398.9%	-4113.1%	-5333.6%	-17576.9%	-5561.0%	-1154.8%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Intelligent Bio Solutions Inc INBS

$7.5M

Sintx Technologies Inc SINT

$10.2M

Beyond Air Inc XAIR

$4.8M

Ainos Inc AIMD

$10.3M

Nexalin Tech NXL

$7.0M

Where Co-Diagnostics Inc Ranks

Frequently Asked Questions

What is Co-Diagnostics Inc's annual revenue?

Co-Diagnostics Inc (CODX) reported $622K in total revenue for fiscal year 2025. This represents a -84.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Co-Diagnostics Inc's revenue growing?

Co-Diagnostics Inc (CODX) revenue declined by 84.1% year-over-year, from $3.9M to $622K in fiscal year 2025.

Is Co-Diagnostics Inc profitable?

No, Co-Diagnostics Inc (CODX) reported a net income of -$47.0M in fiscal year 2025.

What is Co-Diagnostics Inc's EBITDA?

Co-Diagnostics Inc (CODX) had EBITDA of -$49.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Co-Diagnostics Inc's gross margin?

Co-Diagnostics Inc (CODX) had a gross margin of 64.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Co-Diagnostics Inc's return on equity (ROE)?

Co-Diagnostics Inc (CODX) has a return on equity of -227.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Co-Diagnostics Inc's free cash flow?

Co-Diagnostics Inc (CODX) recorded an outflow of $29.8M in free cash flow during fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Co-Diagnostics Inc's operating cash flow?

Co-Diagnostics Inc (CODX) recorded an outflow of $29.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Co-Diagnostics Inc's total assets?

Co-Diagnostics Inc (CODX) had $24.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Co-Diagnostics Inc's capital expenditures?

Co-Diagnostics Inc (CODX) invested $700K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Co-Diagnostics Inc spend on research and development?

Co-Diagnostics Inc (CODX) invested $19.1M in research and development during fiscal year 2025.

How many shares does Co-Diagnostics Inc have outstanding?

Co-Diagnostics Inc (CODX) had 2M shares outstanding as of fiscal year 2025.

What is Co-Diagnostics Inc's current ratio?

Co-Diagnostics Inc (CODX) had a current ratio of 3.87 as of fiscal year 2025, which is generally considered healthy.

What is Co-Diagnostics Inc's debt-to-equity ratio?

Co-Diagnostics Inc (CODX) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Co-Diagnostics Inc's return on assets (ROA)?

Co-Diagnostics Inc (CODX) had a return on assets of -190.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Co-Diagnostics Inc's cash runway?

Based on fiscal year 2025 data, Co-Diagnostics Inc (CODX) had $11.9M in cash against an annual operating cash burn of $29.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Co-Diagnostics Inc's Altman Z-Score?

Co-Diagnostics Inc (CODX) has an Altman Z-Score of -9.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Co-Diagnostics Inc's Piotroski F-Score?

Co-Diagnostics Inc (CODX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Co-Diagnostics Inc's earnings high quality?

Co-Diagnostics Inc (CODX) reported a net loss of $47.0M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.